461350
1-Boc-4-哌啶酮
98%
别名:
N-Boc-4-哌啶酮, 叔丁基4-氧代-1-哌啶羧酸盐
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C10H17NO3
化学文摘社编号:
分子量:
199.25
UNSPSC Code:
12352100
NACRES:
NA.22
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
3650236
Assay:
98%
产品名称
1-Boc-4-哌啶酮, 98%
InChI
1S/C10H17NO3/c1-10(2,3)14-9(13)11-6-4-8(12)5-7-11/h4-7H2,1-3H3
SMILES string
CC(C)(C)OC(=O)N1CCC(=O)CC1
InChI key
ROUYFJUVMYHXFJ-UHFFFAOYSA-N
assay
98%
mp
73-77 °C (lit.)
functional group
ketone
Quality Level
正在寻找类似产品? 访问 产品对比指南
Application
1-Boc-4-哌啶酮，一个制药结构单元，可用于合成（3E，5E）-3,5-双（2,5-二甲氧基亚苄基）-1-叔丁氧基羰基哌啶-4-酮（RL197）。它也可以用于合成含有哌啶环结构的螺吡霉素。
Disclaimer
避免接触金属。
General description
1-Boc-4-哌啶酮在合成药物中被用作前体，同时也是合成选择性配体的合成砌块。
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
法规信息
易制毒化学品（2类）
此项目有
Gebhard Thoma et al.
Journal of medicinal chemistry, 47(8), 1939-1955 (2004-04-02)
The chemokine receptor CCR5 plays an important role in inflammatory and autoimmune disorders as well as in transplant rejection by affecting the trafficking of effector T cells and monocytes to diseased tissues. Antagonists of CCR5 are believed to be of
Marlon Cowart et al.
Journal of medicinal chemistry, 47(15), 3853-3864 (2004-07-09)
A new class of agents with potential utility for the treatment of erectile dysfunction has been discovered, guided by the hypothesis that selective D4 agonists are erectogenic but devoid of the side effects typically associated with dopaminergic agents. The lead
John W Clader et al.
Bioorganic & medicinal chemistry, 12(2), 319-326 (2004-01-16)
Anthranilamide analogues such as 23 are potent and highly selective muscarinic M2 antagonists that also show good oral bioavailability and in vivo activity.
In Ho Kim et al.
Bioorganic & medicinal chemistry letters, 17(5), 1181-1184 (2006-12-27)
A novel series of spirorifamycins was synthesized and their antibacterial activity evaluated both in vitro and in vivo. This new series of rifamycins shows excellent activity against Staphylococcus aureus that is equivalent to rifabutin. However, some compounds of the series
Atsuya Takami et al.
Bioorganic & medicinal chemistry, 12(9), 2115-2137 (2004-04-15)
Several structurally unrelated scaffolds of the Rho kinase inhibitor were designed using pharmacophore information obtained from the results of a high-throughput screening and structural information from a homology model of Rho kinase. A docking simulation using the ligand-binding pocket of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持